Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants
Status: Enrolling
Updated:  12/31/1969
Research Site US130
520
mi
from 91732
Fort Defiance, AZ
A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants
Status: Enrolling
Updated: 12/31/1969
Research Site US130
520
mi
from 91732
Fort Defiance, AZ
Click here to add this to my saved trials
A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants
Status: Enrolling
Updated:  12/31/1969
Research Site US123
345
mi
from 91732
Phoenix, AZ
A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants
Status: Enrolling
Updated: 12/31/1969
Research Site US123
345
mi
from 91732
Phoenix, AZ
Click here to add this to my saved trials
A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants
Status: Enrolling
Updated:  12/31/1969
Research Site US129
461
mi
from 91732
Whiteriver, AZ
A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants
Status: Enrolling
Updated: 12/31/1969
Research Site US129
461
mi
from 91732
Whiteriver, AZ
Click here to add this to my saved trials
A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants
Status: Enrolling
Updated:  12/31/1969
Research Site US114
13
mi
from 91732
Huntington Park, CA
A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants
Status: Enrolling
Updated: 12/31/1969
Research Site US114
13
mi
from 91732
Huntington Park, CA
Click here to add this to my saved trials
A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants
Status: Enrolling
Updated:  12/31/1969
Research Site US127
14
mi
from 91732
Los Angeles, CA
A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants
Status: Enrolling
Updated: 12/31/1969
Research Site US127
14
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants
Status: Enrolling
Updated:  12/31/1969
Research Site US119
725
mi
from 91732
Idaho Falls, ID
A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants
Status: Enrolling
Updated: 12/31/1969
Research Site US119
725
mi
from 91732
Idaho Falls, ID
Click here to add this to my saved trials
A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants
Status: Enrolling
Updated:  12/31/1969
Research Site US031
1152
mi
from 91732
Hutchinson, KA
A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants
Status: Enrolling
Updated: 12/31/1969
Research Site US031
1152
mi
from 91732
Hutchinson, KA
Click here to add this to my saved trials
A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants
Status: Enrolling
Updated:  12/31/1969
Research Site US126
1499
mi
from 91732
Alexandria, LA
A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants
Status: Enrolling
Updated: 12/31/1969
Research Site US126
1499
mi
from 91732
Alexandria, LA
Click here to add this to my saved trials
A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants
Status: Enrolling
Updated:  12/31/1969
Research Site US088
2424
mi
from 91732
Neptune, NJ
A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants
Status: Enrolling
Updated: 12/31/1969
Research Site US088
2424
mi
from 91732
Neptune, NJ
Click here to add this to my saved trials
A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants
Status: Enrolling
Updated:  12/31/1969
Research Site US131
535
mi
from 91732
Gallup, NM
A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants
Status: Enrolling
Updated: 12/31/1969
Research Site US131
535
mi
from 91732
Gallup, NM
Click here to add this to my saved trials
A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants
Status: Enrolling
Updated:  12/31/1969
Research Site US116
1421
mi
from 91732
Beaumont, TX
A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants
Status: Enrolling
Updated: 12/31/1969
Research Site US116
1421
mi
from 91732
Beaumont, TX
Click here to add this to my saved trials
A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants
Status: Enrolling
Updated:  12/31/1969
Research Site US083
1195
mi
from 91732
Fort Worth, TX
A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants
Status: Enrolling
Updated: 12/31/1969
Research Site US083
1195
mi
from 91732
Fort Worth, TX
Click here to add this to my saved trials
A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants
Status: Enrolling
Updated:  12/31/1969
Research Site US128
1349
mi
from 91732
Houston, TX
A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants
Status: Enrolling
Updated: 12/31/1969
Research Site US128
1349
mi
from 91732
Houston, TX
Click here to add this to my saved trials
A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants
Status: Enrolling
Updated:  12/31/1969
Research Site US125
1172
mi
from 91732
Lampasas, TX
A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants
Status: Enrolling
Updated: 12/31/1969
Research Site US125
1172
mi
from 91732
Lampasas, TX
Click here to add this to my saved trials
A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants
Status: Enrolling
Updated:  12/31/1969
Research Site US121
567
mi
from 91732
Salt Lake City, UT
A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants
Status: Enrolling
Updated: 12/31/1969
Research Site US121
567
mi
from 91732
Salt Lake City, UT
Click here to add this to my saved trials
A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants
Status: Enrolling
Updated:  12/31/1969
Research Site US008
569
mi
from 91732
Salt Lake City, UT
A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants
Status: Enrolling
Updated: 12/31/1969
Research Site US008
569
mi
from 91732
Salt Lake City, UT
Click here to add this to my saved trials
A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants
Status: Enrolling
Updated:  12/31/1969
Research Site US134
mi
from 91732
Aurora, CO
A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants
Status: Enrolling
Updated: 12/31/1969
Research Site US134
mi
from 91732
Aurora, CO
Click here to add this to my saved trials
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1606
mi
from 91732
Springfield, IL
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1606
mi
from 91732
Springfield, IL
Click here to add this to my saved trials
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2306
mi
from 91732
Tamarac, FL
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2306
mi
from 91732
Tamarac, FL
Click here to add this to my saved trials
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2301
mi
from 91732
Baltimore, MD
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2301
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1966
mi
from 91732
Detroit, MI
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1966
mi
from 91732
Detroit, MI
Click here to add this to my saved trials
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
873
mi
from 91732
Butte, MT
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
873
mi
from 91732
Butte, MT
Click here to add this to my saved trials
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2409
mi
from 91732
Somers Point, NJ
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2409
mi
from 91732
Somers Point, NJ
Click here to add this to my saved trials
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2375
mi
from 91732
Philadelphia, PA
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2375
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1357
mi
from 91732
Houston, TX
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
16
mi
from 91732
San Dimas, CA
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
16
mi
from 91732
San Dimas, CA
Click here to add this to my saved trials
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
29
mi
from 91732
Sylmar, CA
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
29
mi
from 91732
Sylmar, CA
Click here to add this to my saved trials
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1813
mi
from 91732
Louisville, KY
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1813
mi
from 91732
Louisville, KY
Click here to add this to my saved trials
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2578
mi
from 91732
Boston, MA
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2102
mi
from 91732
Charlotte, NC
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2102
mi
from 91732
Charlotte, NC
Click here to add this to my saved trials
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1880
mi
from 91732
Cincinnati, OH
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1880
mi
from 91732
Cincinnati, OH
Click here to add this to my saved trials
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2032
mi
from 91732
Cleveland, OH
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2032
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2356
mi
from 91732
Malvern, PA
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2356
mi
from 91732
Malvern, PA
Click here to add this to my saved trials
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
25
mi
from 91732
Fountain Valley, CA
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
25
mi
from 91732
Fountain Valley, CA
Click here to add this to my saved trials
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
24
mi
from 91732
Torrance, CA
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
24
mi
from 91732
Torrance, CA
Click here to add this to my saved trials
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
Status: Enrolling
Updated:  12/31/1969
mi
from 91732
Haverford, PA
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
Status: Enrolling
Updated: 12/31/1969
mi
from 91732
Haverford, PA
Click here to add this to my saved trials
Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
1569
mi
from 91732
Saint Louis, MO
Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
1569
mi
from 91732
Saint Louis, MO
Click here to add this to my saved trials
Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center
2277
mi
from 91732
Bethesda, MD
Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center
2277
mi
from 91732
Bethesda, MD
Click here to add this to my saved trials
Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated:  12/31/1969
NCI - Center for Cancer Research
2277
mi
from 91732
Bethesda, MD
Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated: 12/31/1969
NCI - Center for Cancer Research
2277
mi
from 91732
Bethesda, MD
Click here to add this to my saved trials
Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated:  12/31/1969
Ohio State University Comprehensive Cancer Center
1959
mi
from 91732
Columbus, OH
Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated: 12/31/1969
Ohio State University Comprehensive Cancer Center
1959
mi
from 91732
Columbus, OH
Click here to add this to my saved trials
Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University-Sidney Kimmel Cancer Center
2302
mi
from 91732
Baltimore, MD
Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University-Sidney Kimmel Cancer Center
2302
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated:  12/31/1969
Montefiore Medical Center-Einstein Campus
2441
mi
from 91732
Bronx, NY
Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center-Einstein Campus
2441
mi
from 91732
Bronx, NY
Click here to add this to my saved trials
Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated:  12/31/1969
Montefiore Medical Center - Moses Campus
2439
mi
from 91732
Bronx, NY
Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center - Moses Campus
2439
mi
from 91732
Bronx, NY
Click here to add this to my saved trials
Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
2203
mi
from 91732
Durham, NC
Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
2203
mi
from 91732
Durham, NC
Click here to add this to my saved trials
T2Bacteria Panel Pivotal Study
Status: Enrolling
Updated:  12/31/1969
Henry Ford Health System
1965
mi
from 91732
Detroit, MI
T2Bacteria Panel Pivotal Study
Status: Enrolling
Updated: 12/31/1969
Henry Ford Health System
1965
mi
from 91732
Detroit, MI
Click here to add this to my saved trials
T2Bacteria Panel Pivotal Study
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Medical Center
2121
mi
from 91732
Pittsburgh, PA
T2Bacteria Panel Pivotal Study
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Medical Center
2121
mi
from 91732
Pittsburgh, PA
Click here to add this to my saved trials
T2Bacteria Panel Pivotal Study
Status: Enrolling
Updated:  12/31/1969
Rhode Island Hospital
2562
mi
from 91732
Providence, RI
T2Bacteria Panel Pivotal Study
Status: Enrolling
Updated: 12/31/1969
Rhode Island Hospital
2562
mi
from 91732
Providence, RI
Click here to add this to my saved trials
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1786
mi
from 91732
Huntsville, AL
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1786
mi
from 91732
Huntsville, AL
Click here to add this to my saved trials
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
353
mi
from 91732
Daly City, CA
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
353
mi
from 91732
Daly City, CA
Click here to add this to my saved trials
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
311
mi
from 91732
Los Gatos, CA
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
311
mi
from 91732
Los Gatos, CA
Click here to add this to my saved trials